tbuckley/cabot-search huggingface dataset:
Harding-Passey Melanoma, &lt;italic&gt;obob&lt;/italic&gt; Genotype, Age, and High Environmental Temperature as Modifiers of the Anaerobic Glycolytic Capacity of Mouse Kidneys
Authors: George L. Wolff
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article Harding-Passey Melanoma, obob Genotype, Age, and High Environmental Temperature as Modifiers of the Anaerobic Glycolytic Capacity of Mouse Kidneys Get access George L. Wolff George L. Wolff National Cancer Institute,4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 5, April 1956, Pages 1249–1255, https://doi.org/10.1093/jnci/16.5.1249 Published: 01 April 1956 Article history Received: 16 November 1955 Published: 01 April 1956
Malignancy-associated microangiopathic hemolytic anemia.
Authors: D Schiller
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.6.2474 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9196164 Malignancy-associated microangiopathic hemolytic anemia. D SchillerxD SchillerSearch for articles by this author Show More Elisabethinen Hospital, Linz, Austria. https://doi.org/10.1200/JCO.1997.15.6.2474 PDF "Malignancy-associated microangiopathic hemolytic anemia.." Journal of Clinical Oncology, 15(6), pp. 2474–2475© 1997 by American Society of Clinical Oncology
Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides
Authors: Suzanne van Santen, Rachel E. J. Roach, Remco van Doorn, Barbara Horváth, Marjolein S. Bruijn, Cornelus J. G. Sanders, Jacco C. de Pooter, Michelle M. van Rossum, Ellen R. M. de Haas, Joep C. J. M. Veraart, Marcel W. Bekkenk, Maarten H. Vermeer, Rein Willemze
Journal: JAMA Dermatology (2016)

IMPORTANCELarge case series suggest that patients with folliculotropic mycosis fungoides (FMF) have a worse prognosis than patients with classic mycosis fungoides (MF).However, recent studies described a subgroup of patients with FMF with a more favorable prognosis.Distinction between indolent and aggressive FMF may have important therapeutic consequences but is hampered by the inability of the current tumor-node-metastasis-blood (TNMB) staging system to classify patients with FMF in a clinically meaningful way.OBJECTIVE To differentiate between indolent and aggressive FMF using clinicopathological criteria and to define prognostic factors in patients with FMF. DESIGN, SETTING, AND PARTICIPANTSIn this prospective cohort study, we followed 203 patients with FMF, included in the Dutch Cutaneous Lymphoma Registry between October 1985 and May 2014 at a tertiary referral center hosting the Dutch Cutaneous Lymphoma Registry.Overall, 220 patients with FMF had been registered, but 17 patients with incomplete follow-up data or a history of classic MF were excluded. MAIN OUTCOMES AND MEASURESMain outcomes included clinical and histological characteristics, disease progression, and survival.Prognostic factors were investigated using Cox proportional hazard regression analysis.Distinction between early plaque-stage FMF and advanced plaque-stage FMF was made by a blinded review of skin biopsy specimens from patients presenting with plaques. RESULTSIn a cohort of 147 men and 56 women (median [range] age, 59 [15-93] years), patients with histologically early plaque-stage FMF had a very similar overall survival (OS) rate to patients with only patches and/or follicular papules (10-year OS, 71% vs 80%), while the survival rate of patients with histologically advanced plaque-stage FMF was almost identical to that of patients presenting with tumors (10-year OS, 25% vs 27%).Subsequently, 3 clinical subgroups with significantly different survival data were distinguished: early skin-limited FMF (group A; n = 84; 5-year and 10-year OS, 92% and 72%); advanced skin-limited FMF (group B; n = 102; 5-year and 10-year OS, 55% and 28%); and FMF presenting with extracutaneous disease (group C; n = 17; 5-year and 10-year OS, 23% and 2%).Age at diagnosis, large cell transformation and secondary bacterial infection were independent risk factors for disease progression and/or poor survival. CONCLUSIONS AND RELEVANCEThe results of this study provide useful criteria to differentiate between indolent and aggressive FMF and confirm the existence of a subgroup of FMF with a favorable prognosis.
Magnetic compression anastomosis for patients with a disconnected bile duct after living-donor related liver transplantation: a pilot study
Authors: Galip Ersoz, Fatih Tekin, Halil Bozkaya, Mustafa Parildar, Ilker Turan, Zeki Karasu, Omer Ozutemiz, Oktay Tekesin
Journal: Endoscopy (2016)

We present the use of the magnetic compression anastomosis (MCA) technique for treatment of disconnected bile duct after living-donor related liver transplantation (LDLT) using the recently introduced through-the-scope magnet.The MCA technique was used in patients with disconnected bile duct who could not be treated with either percutaneous or endoscopic procedures. All patients already had a percutaneous external biliary drainage catheter before the procedure. The magnet was placed percutaneously into the proximal side of the obstruction by pushing a 5-Fr catheter over a guidewire. Concurrently, endoscopic retrograde cholangiopancreatography (ERCP) including endoscopic papillary sphincterotomy was performed. The sister magnet was then carefully advanced to the opposite side of the obstruction with a 5-Fr catheter over a guidewire. After the confirmation of biliary recanalization, a guidewire was passed through the stricture and a percutaneous dilation of the stricture was performed with a balloon-tipped catheter. Endoscopic balloon dilation of the stricture, insertion of two plastic stents and the removal of the internal drainage catheter were performed during the first ERCP session. Stent exchange and multiple side-by-side stent placements were planned at regular intervals (3 monthly) for all patients.A total of six LDLT patients with disconnected bile duct (aged 37 - 68, four men) underwent the MCA technique between September 2014 and July 2015. Biliary recanalization was achieved 13 - 42 days after the magnet placement procedure. The success rate of the procedure was 100 %.The MCA technique using a small magnet (diameter 2.4 mm) is effective and useful in LDLT patients with disconnected bile duct.
Government blocked guidance that urged minimum staff ratios in emergency departments
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Hospitals in England were told to implement minimum nurse to patient ratios in emergency departments, in guidance that was blocked from publication by the government.

The National Institute for Health and Care Excellence (NICE) had recommended that minimum levels of nursing cover should be employed across all major emergency departments to ensure patient safety. Its stipulations included two registered nurses to each major trauma patient, two to each …
OC-017 Multi-centre audit of management and outcome in autoimmune hepatitis (aih) – preliminary results
Authors: VM Gordon
Journal: Gut (2015)

<h3>Introduction</h3> There are few data on presenting features of AIH outside large centres. We report data from an outcome audit of AIH in 28 UK centres of varying size. <h3>Method</h3> We collected all prevalent cases since 2000 and all incident cases since 2007 by searching electronic patient letters, histology databases and hospital coding. Case validation was by 1999 International AIH Group diagnostic criteria. We used a web-based data collection system. <h3>Results</h3> Of 1109 patients (227 prevalent 882 incident) with/treated as AIH, 80% were women. Age at diagnosis was (median (range)) 55 (8–86)years. Age distribution was similar in women and men. There were 91% Caucasian, 7% Asian, 1% Afro-Caribbean and 0.1% Chinese.39% had a personal/family history of autoimmune disease: 14% with thyroiditis/hypothyroidism, 10% PBC, 4% IBD and 3% coeliac disease. HBV and HCV serology was negative in 1061 (96%) patients and was undocumented in 42 (4%). Six patients (0.5%) had acute hepatitis IgM antibodies (4 CMV, 1 EBV and CMV, 1 HEV). ANA was present in 57%, ASMA in 47% and Anti-LKM1 in 2%; ≥1 one was found in 80%. AMA was found in 9%. Serum IgG/globulin was raised in 78%. Seventy four patients (7%) did not meet IAIHG diagnostic criteria but were treated as AIH. Presenting symptoms were: none 22%, jaundice/itching 42%, fatigue 35%, nausea 14%, weight loss 13%, abdominal pain 16%, joint aches 12%, flu-symptoms 6%, rash 3%, amenorrhoea 0.4%, others 8%. Time from first abnormal liver tests to diagnosis was 3 (0–167), months and was shorter in patients presenting with jaundice/pruritus than in others: 1 vs 5 months; (p = &lt; 0.0001). At presentation, 4.4% had ascites, 5.5% oedema, 1.9% encephalopathy, 0.7% variceal bleeding and 8.4% had clinical decompensation (≥1 of these). In another 13%, MELD score was &gt;15. 96% of patients had a diagnostic liver biopsy of which 23% had cirrhosis (Ishak fibrosis stage 5/6). Of 1030 treated patients (day one prescription) 1003 initially received a steroid: prednisolone (30 (2–60) mg/day) in 91%, budesonide (3–9 mg/day) in 5%, methylprednisolone in 1.6% and hydrocortisone in 0.1%. Of these, 11% received concurrent Azathioprine, 0.2% 6-Mercaptopurine (6-MP), 3% Mycophenolate, 2% Tacrolimus and 0.2% biological agents. Of those not receiving steroids initially (N = 27), 21 received AZA, 3 6 MP, 1 MMF, and 2 a biologic agent. <h3>Conclusion</h3> In this large multicentre cohort of UK AIH patients, 23% had cirrhosis and 22% had liver decompensation at presentation. Delay in diagnosis was often many months, especially in those without jaundice. 4% did not have documented HBV/HCV serology and 7% did not meet IAIHG criteria. There is significant variation in initial treatment of AIH. <h3>Disclosure of interest</h3> None Declared.
The Effect of Methylcholanthrene on the Frog's Kidney&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Hans G. Schlumberger
Journal: JNCI Journal of the National Cancer Institute (1948)

Journal Article The Effect of Methylcholanthrene on the Frog's Kidney Get access Hans G. Schlumberger Hans G. Schlumberger Department of Pathology, College of Medicine, Ohio State University, Columbus, Ohio Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 9, Issue 2, October 1948, Pages 111–118, https://doi.org/10.1093/jnci/9.2.111 Published: 01 October 1948 Article history Received: 07 June 1948 Published: 01 October 1948
Soundings: Spaced out
Authors: Liam Farrell
Journal: BMJ (1999)

Those were the days: the Apollo missions, fuzzy pictures from the moon, Also Sprach Zarathustra, James Burke, and Patrick Moore jumping up and down with an ingenuous and guileless excitement that was irresistibly infectious. It seemed that a new age was dawning and the uncluttered truths of science would provide all the answers.

But the blissful unimpeached Arcady was not to last, and because of this the word “comet” to me has never suggested a magnificent ball of fire hurtling across the solar system, with a shimmering silver tail a million miles long. Rather it implies shattered dreams and busted expectations, because I remember all too clearly the bitter disappointment of Comet Kohoutek in the 1970s (and also, a sheer coincidence, that no girls would go out with me).

“It’ll be half the size of the moon,” enthused Patrick Moore, who had never lied to me before, and whom I—still just a kid with stars in my eyes—really believed. But my faith in him and my boyhood dreams were to be utterly betrayed, for when Comet Kohoutek eventually arrived it was as ineffectual as a cough bottle from the British National Formulary and as bright as a psychiatrist needs to be.

And the busted expectations continued: John F Kennedy, antibiotics, interferon, Ben Johnson; morning glories with feet of clay.

So I had no hopes for Comet Hale-Bopp whatsoever, despite all the advance publicity. I’d heard that song before, and it had broken my youthful heart, so I didn’t even bother looking up in the sky for it. Until one night, I was lamenting my disenchantment over a few beers with my good friend Petie.

“You mean you haven’t seen it yet?” he said in surprise. “It’s been up there for two months now.”

“Well, where is it then?” I said, wondering when exactly he had become such an astronomical expert, if he was as busy looking after his cows as he said he was.

“It’s right over my house,” he said emphatically.

Very droll for a hillbilly, I thought, but the very next night I was travelling over the mountains and I stopped the car to look, and ... there it was, shining like a beacon in the sky, tail streaming out like a little piece of heaven, Comet Hale-Bopp in a rainbow of glory, and, as promised, right above Petie’s house.

Dreams do come true, Dorothy, and sometimes right in our own backyard.
Subphrenic hematoma mimicking malpositioned gallbladder during endoscopic retrograde cholangiopancreatography
Authors: Yo Jeong, Tae Kim, Kook Kim
Journal: Endoscopy (2015)

A 60-year-old woman with recurrent upper abdominal pain of 10 days' duration visited our hospital. Abdominal computed tomography demonstrated a stone in the common bile duct (CBD), and endoscopic retrograde cholangiopancreatography (ERCP) was performed to remove it. The patient's hematological and clotting parameters were normal.
Endoscopic ultrasound-guided fine-needle aspiration of a pulmonary artery malignant thrombus
Authors: Rodica Gincul, Victoria Gomez, Sarah Kerr, Jun Zhang, Michael Levy
Journal: Endoscopy (2015)

Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a standard technique for sampling mediastinal disease. The need for transvascular sampling or sampling within major mediastinal vessels seldom arises [1]. Herein, we report a case of EUS-FNA of a pulmonary artery thrombus in a patient with pancreatic carcinoma that demonstrates the impact of EUS.
Prognostic Value of Intrinsic Subtypes in Hormone Receptor–Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib
Authors: Aleix Prat, Maggie C. U. Cheang, Patricia Galván, Paolo Nuciforo, Laia Paré, Barbara Adamo, Montserrat Muñoz, Margarida Viladot, Michael F. Press, Robert Gagnon, Catherine Ellis, Stephen Johnston
Journal: JAMA Oncology (2016)

The value of the intrinsic subtypes of breast cancer (luminal A, luminal B, human epidermal growth factor receptor 2 [currently known as ERBB2, but referred to as HER2 in this study]-enriched, and basal-like) in the metastatic setting is currently unknown.To evaluate the association of the intrinsic subtypes of breast cancer with outcome and/or benefit in hormone receptor (HR)-positive metastatic breast cancer.Unplanned retrospective analysis of 821 tumor samples (85.7% primary and 14.3% metastatic) from the EGF30008 phase 3 clinical trial (NCT00073528), in which postmenopausal women with HR-positive invasive breast cancer and no prior therapy for advanced or metastatic disease were randomized to letrozole with or without lapatinib, an epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor. Tumor samples were classified into each subtype using the research-based PAM50 classifier. Prior neoadjuvant/adjuvant antiestrogen therapy was allowed. Patients with extensive symptomatic visceral disease were excluded. Treatment effects were evaluated using interaction tests.Primary and secondary end points were progression-free survival and overall survival.The median (range) age was 62 (31-94) years. Intrinsic subtype was the strongest prognostic factor independently associated with progression-free survival and overall survival in all patients, and in patients with HER2-negative (n = 644) or HER2-positive (n = 157) diseases. Median progression-free survival differed across the intrinsic subtypes of clinically HER2-negative disease: luminal A (16.9 [95% CI, 14.1-19.9] months), luminal B (11.0 [95% CI, 9.6-13.6] months), HER2-enriched (4.7 [95% CI, 2.7-10.8] months), and basal-like (4.1 [95% CI, 2.5-13.8] months). Median OS also differed across the intrinsic subtypes: luminal A (45 [95% CI, 41-not applicable {NA}] months), luminal B (37 [95% CI, 31-42] months), HER2-enriched (16 [95% CI, 10-NA] months), and basal-like (23 [95% CI, 12-NA] months). Patients with HER2-negative/HER2-enriched disease benefited from lapatinib therapy (median PFS, 6.49 vs 2.60 months; progression-free survival hazard ratio, 0.238 [95% CI, 0.066-0.863]; interaction P = .02).This is the first study to reveal an association between intrinsic subtype and outcome in first-line HR-positive metastatic breast cancer. Patients with HR-positive/HER2-negative disease with a HER2-enriched profile may benefit from lapatinib in combination with endocrine therapy. The clinical value of intrinsic subtyping in hormone receptor-positive metastatic breast cancer warrants further investigation, but patients with luminal A/HER2-negative metastatic breast cancer might be good candidates for letrozole monotherapy in the first-line setting regardless of visceral disease and number of metastases.
PTU-291 Managing gi consequences of cancer treatment- what does it cost?
Authors: A Muls, C Marshall, A Lalji, L Butler, H Andreyev
Journal: Gut (2015)

<h3>Introduction</h3> The considerable GI toxicity experienced by patients during and after cancer therapy is an increasing problem as more patients survive cancer, yet struggle to obtain adequate assessment or treatment. <h3>Method</h3> A financial model was derived from a prospective evaluation of patients referred to a GI consequences of cancer treatment clinic, where patients are investigated and treated using an algorithm proven to be effective. The costs of assessment, investigations and prescriptions was calculated using the National Tariffs 2013/14. The clinical team includes a Consultant Gastroenterologist, a Nurse Consultant and a specialist dietetic service. This model does not include overhead costs such as administrative support, clinic space and laboratory staff costs. <h3>Results</h3> The figures are based on the profiles of 326 consecutive patients discharged from our GI and Nutrition Team service between 01 April 2013 and 31 March 2014. This was a mixed cohort of men and women previously treated for urological (43%), gynaecological (21%), colorectal (12%), upper GI (10%) and other (14%) cancers. Initial out-patient consultation costs £192, investigations with related prescription costs (e.g. bowel preparation, SeHCAT capsule) £890 and follow up and treatment costs £438 (mean £1520 per patient). Annual NHS costs for cancer services are £5 billion, but the cost to society as a whole – including loss of productivity – is £18.3 billion (DoH, 2013). The NHS tariff for a person diagnosed with prostate cancer and treated with radiotherapy lies between £6,000 and £9,000. The tariff paid per woman treated with chemoradiation for cervical cancer is £14,800. Treatment for colon cancer with a right hemicolectomy followed by adjuvant capecitebine costs £8,300; anterior resection costs £10,800; long course chemoradiation (capecitabine and oxaliplatin) followed by surgery and adjuvant chemotherapy (capecitebine) costs &gt;£45,000. Surgery for upper GI cancer costs £10,500 while additional chemotherapy adds £2,000-£6,000. A pylorus preserving Whipple procedure followed by adjuvant chemoradiation with epirubicin, cisplatin and capecitebine for pancreatic cancer costs £15,900. These are acute costs and do not include the costs of follow up or investigating and treating relapse. <h3>Conclusion</h3> Specialist assessment and treatment of GI consequences of cancer therapies seems extremely good value in comparison to the cost of treating the cancer. So it is unclear why it has proven so difficult to obtain funding for specialist services to manage these issues which can have a devastating effect on daily activity. Lack of adequate assessment and treatment not only leads to a burden to the patient and their family, but potentially unnecessary ongoing costs to society and other clinical services. <h3>Disclosure of interest</h3> None Declared.
Hepatoearcinogenesis by 2-Aeetylaminofluorene and Related Compounds Including Comments on Dietary and Other Influences&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;
Authors: H P MORRIS
Journal: JNCI Journal of the National Cancer Institute (1955)

Hepatoearcinogenesis by 2-Aeetylaminofluorene and Related Compounds Including Comments on Dietary and Other Influences Harold P. Moeris Harold P. Moeris Laboratory of Biochemistry, National Cancer Institute,2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1535–1547, https://doi.org/10.1093/jnci/15.Supplement_5.1535 Published: 01 April 1955
Psychiatric training issues: the Puerto Rican perspective
Authors: A A Arce
Journal: American Journal of Psychiatry (1982)

A critical aspect of the problem of mental health service delivery to Hispanics is the inadequacy of manpower resources, especially the lack of professional workers with a knowledge of the Hispanic culture and language. Two factors--underrepresentation of Hispanics at professional levels and curriculum deficits in training programs--account for the persistence of inadequate manpower. The author discusses both themes from the Puerto Rican perspective, emphasizing the development of didactic and practical learning experiences for both Puerto Rican and non-Hispanic trainees and their implications for diagnosis and treatment. Training models are discussed.